Skip to main content
Neumora Therapeutics, Inc. logo

Neumora Therapeutics, Inc. — Investor Relations & Filings

Ticker · NMRA ISIN · US6409791000 US Manufacturing
Open in API
Filings indexed 222 across all filing types
Latest filing 2022-06-17 Regulatory Filings
Country US United States of America
Listing US NMRA

About Neumora Therapeutics, Inc.

https://neumoratx.com/

Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to redefining neuroscience drug development. The company focuses on creating precision medicines for brain diseases, including neuropsychiatric and neurodegenerative disorders. Neumora utilizes its proprietary 'Precision Toolbox,' an integrated data science platform, to identify patient subtypes and develop targeted therapies with novel mechanisms of action. This approach aims to address the significant unmet medical needs in brain health by applying the principles of precision medicine. The company's pipeline includes navacaprant, a clinical-stage candidate for the treatment of Major Depressive Disorder (MDD).

Recent filings

Filing Released Lang Actions
Regulatory Filings 2022
Regulatory Filings
2022-06-17 English
Regulatory Filings 2022
Regulatory Filings Classification · 100% confidence The document is a letter from legal counsel to the SEC regarding an Amendment No. 3 to a Draft Registration Statement on Form S-1 for Neumora Therapeutics, Inc. It discusses responses to SEC comment letters and revisions to the draft registration statement. The Form S-1 is a registration statement used for securities offerings, not a financial report like an annual or quarterly report. The document is a regulatory submission and correspondence with the SEC, not a report itself. It is not a report publication announcement since it contains substantive responses to SEC comments. Therefore, it fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory documents and correspondence that do not fit other categories.
2022-06-10 English
Capital/Financing Update 2022
Capital/Financing Update Classification · 100% confidence The document is a confidential draft registration statement submitted to the SEC on Form S-1 for Neumora Therapeutics, Inc. It is a preliminary prospectus for an initial public offering (IPO) of common stock. The Form S-1 is a registration statement used by companies planning to go public to register their securities with the SEC. This document includes detailed information about the company, its business, financial data, risk factors, management, and the offering itself. It is not an annual report, earnings release, or any other type of report but a registration statement related to capital raising and securities offering. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2022-06-10 English
Regulatory Filings 2022
Regulatory Filings
2022-05-16 English
Capital/Financing Update 2022
Capital/Financing Update Classification · 100% confidence The document is a confidential draft registration statement submitted to the U.S. Securities and Exchange Commission (SEC) on Form S-1. It is a registration statement under the Securities Act of 1933 for Neumora Therapeutics, Inc. The document includes detailed information typical of an IPO prospectus, such as company overview, risk factors, use of proceeds, management discussion and analysis, executive compensation, principal stockholders, and financial data. It is not a report of financial results, audit, or management discussion alone, but a comprehensive registration document for a public offering. This type of filing is best classified as a Capital/Financing Update (CAP) because it relates to the company's fundraising activities through an initial public offering (IPO).
2022-05-02 English
Regulatory Filings 2022
Regulatory Filings Classification · 95% confidence The document is a letter from a law firm to the SEC regarding an Amendment No. 1 to a Draft Registration Statement on Form S-1 for Neumora Therapeutics, Inc. It discusses responses to SEC comments on the draft registration statement and revisions made. The document is a correspondence related to a registration statement filing, not the registration statement itself or a financial report. It is a regulatory communication and does not contain financial data or report content. The document length is 3723 characters, which is relatively short and consistent with a regulatory filing or comment letter. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other categories.
2022-02-12 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.